MX2024002010A - Vacunas terapeuticas contra el virus del papiloma. - Google Patents
Vacunas terapeuticas contra el virus del papiloma.Info
- Publication number
- MX2024002010A MX2024002010A MX2024002010A MX2024002010A MX2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A MX 2024002010 A MX2024002010 A MX 2024002010A
- Authority
- MX
- Mexico
- Prior art keywords
- therapeutic
- papilloma virus
- virus vaccines
- nucleic acid
- vaccines
- Prior art date
Links
- 229960002566 papillomavirus vaccine Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 241001631646 Papillomaviridae Species 0.000 abstract 1
- 108010076039 Polyproteins Proteins 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21191940.2A EP4137153A1 (en) | 2021-08-18 | 2021-08-18 | Therapeutic papilloma virus vaccines |
| PCT/EP2022/073016 WO2023021116A1 (en) | 2021-08-18 | 2022-08-17 | Therapeutic papilloma virus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002010A true MX2024002010A (es) | 2024-04-18 |
Family
ID=77398487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002010A MX2024002010A (es) | 2021-08-18 | 2022-08-17 | Vacunas terapeuticas contra el virus del papiloma. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250066427A1 (enExample) |
| EP (2) | EP4137153A1 (enExample) |
| JP (1) | JP2024532853A (enExample) |
| KR (1) | KR20240095168A (enExample) |
| CN (1) | CN117940156A (enExample) |
| AU (1) | AU2022331111A1 (enExample) |
| CA (1) | CA3229203A1 (enExample) |
| MX (1) | MX2024002010A (enExample) |
| WO (1) | WO2023021116A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026523389A (ja) * | 2023-05-26 | 2026-07-14 | プロバイオジェン アーゲー | 二倍体組換え核細胞質大型ｄｎａウイルスベクター |
| CN120607593A (zh) * | 2024-03-06 | 2025-09-09 | 诺未生物技术(无锡)有限公司 | 治疗hpv感染相关疾病的药物 |
| CN119569831B (zh) * | 2024-12-13 | 2026-04-28 | 深圳锦时生物科技有限公司 | 一种活性多肽及在预防和/或治疗hpv中的应用 |
| CN122405672A (zh) * | 2025-01-10 | 2026-07-17 | 成都迈科康生物科技股份有限公司 | 一种rna疫苗及其相关产品 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
| EP1427443A4 (en) * | 2001-08-23 | 2006-03-08 | Merck & Co Inc | VACCINES WITH PAPILLOMA VIRUS E PROTEINS DELIVERED BY A VIRAL VECTOR |
| SI1957528T1 (sl) | 2005-11-30 | 2013-02-28 | University Of Copenhagen | Nukleotidno cepivo |
| SI2865387T1 (sl) | 2008-11-21 | 2019-10-30 | Kobenhavns Univ University Of Copenhagen | Primiranje imunskega odziva |
| GB201321384D0 (en) | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| WO2018060288A1 (en) * | 2016-09-29 | 2018-04-05 | Glaxosmithkline Biologicals S.A. | Compositions and methods of treatment of persistent hpv infection |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| US12576143B2 (en) | 2018-10-19 | 2026-03-17 | Nouscom Ag | Teleost invariant chain cancer vaccine |
-
2021
- 2021-08-18 EP EP21191940.2A patent/EP4137153A1/en not_active Withdrawn
-
2022
- 2022-08-17 WO PCT/EP2022/073016 patent/WO2023021116A1/en not_active Ceased
- 2022-08-17 US US18/684,381 patent/US20250066427A1/en active Pending
- 2022-08-17 KR KR1020247008839A patent/KR20240095168A/ko active Pending
- 2022-08-17 MX MX2024002010A patent/MX2024002010A/es unknown
- 2022-08-17 CN CN202280053653.9A patent/CN117940156A/zh active Pending
- 2022-08-17 AU AU2022331111A patent/AU2022331111A1/en active Pending
- 2022-08-17 EP EP22768288.7A patent/EP4387662A1/en active Pending
- 2022-08-17 CA CA3229203A patent/CA3229203A1/en active Pending
- 2022-08-17 JP JP2024510296A patent/JP2024532853A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4387662A1 (en) | 2024-06-26 |
| EP4137153A1 (en) | 2023-02-22 |
| CA3229203A1 (en) | 2023-02-23 |
| AU2022331111A1 (en) | 2024-03-07 |
| WO2023021116A1 (en) | 2023-02-23 |
| US20250066427A1 (en) | 2025-02-27 |
| KR20240095168A (ko) | 2024-06-25 |
| JP2024532853A (ja) | 2024-09-10 |
| CN117940156A (zh) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077396A2 (es) | EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS | |
| CL2024001737A1 (es) | Variantes de nucleasas cas12a y métodos de preparación y uso de las mismas | |
| GEP20257742B (en) | Modified short interfering nucleic acid (sina) molecules and uses thereof | |
| MX340880B (es) | Vacunas mejoradas y metodos para uso de las mismas. | |
| MX2020001655A (es) | Vacuna vph. | |
| CO6480995A2 (es) | Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv | |
| CR20170350A (es) | Dinucleótidos cíclicos útiles en el tratamiento del cáncer | |
| BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
| MX2018004916A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
| UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
| MX2021007241A (es) | Acido ribonucleico (arn) que codifica para una proteina. | |
| CY1111378T1 (el) | Προερχομενα απο κυτταρα ιικα εμβολια με χαμηλα επιπεδα υπολειμματικου κυτταρικου dna | |
| MX2017005788A (es) | Vacunas terapeuticas contra el vph16. | |
| BRPI0913012A2 (pt) | vírus do nilo ocidental/da dengue quiméricos | |
| CL2019000640A1 (es) | Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso. | |
| CY1110349T1 (el) | Βελτιστοποιημενη εκφραση toy hpv 52 l1 σε ζυμη | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| AR071220A1 (es) | Astrovirus aviario depositado bajo el nuero cncm i-3895 | |
| CO2019009815A2 (es) | Combinaciones farmacéuticas | |
| EA201992282A1 (ru) | Усовершенствованные вакцины против вируса папилломы человека и способы их применения | |
| NO20084857L (no) | HPV-16-basert papillomavirus vaksine | |
| EA202092990A2 (ru) | Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу | |
| CR20130424A (es) | Terapéuticos a base de levadura para infección de la hepatitis b crónica | |
| BR112018075420A2 (pt) | melhoramento da imunogenicidade de petídeo l2 | |
| NZ719934A (en) | Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors |